chemieunternehmen.com

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney diseasefocused drug discovery based on patient derived-data. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-nurture-consortium-to-mine-unique-kidney-disease-patient-biobank-5464

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting, which took place today, with the required majority. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/resolutions-of-the-annual-general-meeting-2017-of-evotec-ag-5466

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forge-therapeutics-and-evotec-present-first-efficacy-data-for-lpxc-inhibitor-in-uti-model-at–asm-microbe-2017-5461

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-endometriosis-alliance-with-bayer-5460

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-attend-three-upcoming-investor-conferences-5458

Evotec AG today reported financial results and corporate updates for the first quarter of 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-first-quarter-results-2017-and-corporate-update-5456

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestone-in-diabetes-alliance-with-sanofi-5452

Evotec AG today announced that its partner Forge Therapeutics („Forge“) has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-forge-therapeutics-receives-prestigious-carb-x-research-award-5450

Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fiscal-year-results-2016-leading-innovation-efficiency–first-in-class-drug-discovery-5448